DragonFly System Reinforces Global Clinical Evidence at CSI Frankfurt 2026

Frankfurt, Germany – June 3–6, 2026

At CSI Frankfurt 2026, Valgen Medtech shared one-year outcomes from the DragonFly–DMR EU Pivotal Study, the first European multicenter clinical study of a Chinese-developed transcatheter mitral valve repair system. The results reinforce the DragonFly System's safety, effectiveness, and durability in treating degenerative mitral regurgitation among high-surgical-risk patients.

Beyond the European dataset, Valgen Medtech highlighted growing global clinical experience with the DragonFly System in mitral and tricuspid valve disease, including real-world case series from Türkiye and a live tricuspid TEER case broadcast.

As the first Chinese TMVr device to receive CE approval for both degenerative and functional mitral regurgitation, the DragonFly System represents a significant advancement in structural heart therapy and is positioned to benefit patients worldwide.